Skip to main content

ORIGINAL RESEARCH article

Front. Neurol.
Sec. Neuro-Oncology and Neurosurgical Oncology
Volume 15 - 2024 | doi: 10.3389/fneur.2024.1413236
This article is part of the Research Topic Advances in Brain Tumor Therapy View all 6 articles

Tumor treating induced fields: a new treatment option for patients with glioblastoma

Provisionally accepted
Zehao Cai Zehao Cai 1Kaiyang Zu Kaiyang Zu 2Ying Wang Ying Wang 2Ye Li Ye Li 3Hong Zhao Hong Zhao 3Hanwen Zhao Hanwen Zhao 4Xue Yang Xue Yang 1Can Wang Can Wang 1Tengteng Meng Tengteng Meng 3Tong Xiao Tong Xiao 2Hao Zheng Hao Zheng 2Yonghe Zhao Yonghe Zhao 2Chunli Niu Chunli Niu 3Junzhi Yang Junzhi Yang 3Feng Chen Feng Chen 2Zhi Yang Zhi Yang 2Zou Zhige Zou Zhige 4*Wenbin Li Wenbin Li 1*
  • 1 Beijing Tiantan Hospital, Capital Medical University, Beijing, China
  • 2 Capital Medical University, Beijing, Beijing Municipality, China
  • 3 Kunlun Tripot (Beijing) Medical Technology Co. Ltd, Beijing, China
  • 4 Huazhong University of Science and Technology, Wuhan, Hubei Province, China

The final, formatted version of the article will be published soon.

    Purpose: Currently, a range of electromagnetic therapies, including magnetic field therapy, microcurrents therapy, and tumor treating fields, are under investigation for their potential in central nervous system tumor research. Each of these electromagnetic therapies possesses distinct effects and limitations. Our focus is on overcoming these limitations by developing a novel electric field generator. This generator operates by producing alternating induced currents within the tumor area through electromagnetic induction.Methods: Finite element analysis was employed to calculate the distribution of electric fields. Cell viability was assessed using the CCK-8 assay. Tumor volumes and weights served as indicators to evaluate the effectiveness of TTIF. The in-vivo imaging system was utilized to confirm tumor growth in the brains of mice.Results: TTIF significantly inhibited the proliferation of U87 cells both in vitro and in vivo. Conclusion: TTIF significantly inhibited the proliferation of U87 cells both in vitro and in vivo. Consequently, TTIF emerges as a potential treatment option for patients with progressive or metastatic GBM.

    Keywords: Electromagnetic therapy, Glioblastoma, Central Nervous System, electromagnetic induction, transformer

    Received: 06 Apr 2024; Accepted: 10 Sep 2024.

    Copyright: © 2024 Cai, Zu, Wang, Li, Zhao, Zhao, Yang, Wang, Meng, Xiao, Zheng, Zhao, Niu, Yang, Chen, Yang, Zhige and Li. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence:
    Zou Zhige, Huazhong University of Science and Technology, Wuhan, 430074, Hubei Province, China
    Wenbin Li, Beijing Tiantan Hospital, Capital Medical University, Beijing, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.